aml/cml Flashcards
describe the molecular name and characteristics (4) of t(8;21)
AML1-ETO aka RUNX1-Runx1t1 – . Aur rods, chloromas, often CNS+. Good prognosis
molecular name and characteristics(4): inv(16)/t(16;16)
CBFB-MYH11, eosinophils with basophilic granules, chloromas, CNS+, good prognosis
molecular name and characteristics of t(15;17)
PML-RARA– this is garnules/auer rods, DIC/bleeding, good prognosis (with ATRA and arsenic )
molecular and characteristics of abnormal 11q23
kmt2a- this is the infant, WBC, skin/CNS/gums, t-AML after a typo II inhibitor
what are the myeloid leukemia predispositions that increase risk of JMML
RASopathies– NF1, CBL syndrome, noonans
name 3 marrow failure syndromes that predispose for MDSz sn AML
severe congenital neutropenia, schwachman diamond, and fanconi anemia
neutropenia, pancreatic insufficiency, skeletal abnormalities- name disorder and gene
schwachman diamond- SBDS mutations
severe congenital neutropenia- another name for it and most common genes and what they do
kostmann syndrome. utations in ELA2 is most common. agranlocytosis. secondary activating mutations of GCSF receptor
gene for congenital amegakaryocytic thrombocytopenia
MPL (thrombopoietin receptor)
alkylating agents causing myeloid diseae– what is latency and cytogenetics
5-7 yard (long) cytogenetics are -7, del(7q), -5, del (5q) and complex cytogentics
radiation causing myeloid diseae– what is latency and cytogenetics
5-7 yard (long) cytogenetics are -7, del(7q), -5, del (5q) and complex cytogentics
topoisomerase inhibitors- name the drugs, latency, and cytogenetics (5)
etoposide > anthracyclines. short latency (1-2 years), usually KMT2aR but also 8;21, 15;17, 9;22, and inv(16)
3 surface receptors on AML in kid with T21
AMKL– CD41a, CD42, CD61
for kids with TMD, when do they usually get AML
by age 3
common presentation for AML in kid with T21
isolated thrombocytopenia
characteristic of APL that is high risk
WBC more than 10k
name 2 cytogenetic and 2 molecular findings for favorable or LR AML
cytogenetic: inv(16) or t(8;21). Molecular: NPM1, CEBPA
name 3 unfavorable or HR cytogenetic changes for AML
-7. 5q-, abn(3q)
def of primary induction failure for AML
more than 5% blasts after course 2
genetic finding commonly in AMML with eosinophilia
inv(16)
which type of AML commonly has myelofibrosis
acute megakaryoblstaic (in T21)
define RAM phenotype (immunophentoype and common genetic fusion)
bright CD56, dim (or negative) CD45, dim (or neg) CD38) and negative HLA-DR. Associated with CBFA2T3;;GLIS2 fusion
standard way to induce remission for AML
2 courses of intense (doxo + cytarabine, sometime with etoposide) and gemtuzumab
what is AML consolidation
high dose ara-C